The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

12 articles for DS Clarke


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.EBI
Astrazeneca
Identification, optimization, and pharmacology of acylurea GHS-R1a inverse agonists.EBI
Astrazeneca
Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.EBI
Astrazeneca
Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.EBI
Astrazeneca
Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.EBI
Astrazeneca
Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life.EBI
Astrazeneca R&D
 
Design of dual-acting thromboxane antagonist-synthase inhibitors by a mutual prodrug approachEBI
TBA
Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity.EBI
Astrazeneca
A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase.EBI
Astrazeneca
Quinuclidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase: optimization from lipid profiles.EBI
Zeneca Pharmaceuticals
Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors.EBI
Zeneca Pharmaceuticals
A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors.EBI
Zeneca Pharmaceuticals